In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden

Autor: Angela Camporeale, Chaitanya Tellapragada, Jelena Kornijenko, Carl Erik Nord, Christian G. Giske

Publikováno v: Microbiology Spectrum, Vol 9, Iss 2 (2021)

ABSTRACT Clostridioides difficile infection represents a growing clinical challenge. The new compound omadacycline is a potential treatment alternative, as many antibiotics have limited activity or are rarely used due to costs and side effects. The a

Externí odkaz: https://doaj.org/article/7fd4e2790bbd4f32b0d4a236f3d2916c

Molecular characteristics of Clostridium difficile strains from patients with a first recurrence more than 8 weeks after the primary infection

Autor: Yijian Chen, Mamun Ur Rashid, Haihui Huang, Hong Fang, Carl Erik Nord, Minggui Wang, Andrej Weintraub

Publikováno v: Journal of Microbiology, Immunology and Infection, Vol 50, Iss 4, Pp 532-536 (2017)

Background/Purpose: Nearly all published studies of recurrent Clostridium difficile infections (CDI) report recurrent CDI within 8 weeks after the primary infection. This study explored the molecular characteristics of C. difficile isolates from the

Externí odkaz: https://doaj.org/article/de39cbf9171245adb14f210ccbc791b1

Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials

Autor: John Pullman, Thomas J. Louie, Liliana Preotescu, Hilke Kracker, Simon Grill, George H. Talbot, Dale N. Gerding, Iulian Gheorghe Diaconescu, Claudia Murta de Oliveira, Mark H. Wilcox, Martha Buitrago, Anne Claire Marrast, Oliver A. Cornely, Carl Erik Nord

Publikováno v: The Lancet Infectious Diseases. 19:265-274

Summary Background Cadazolid is a novel quinoxolidinone antibiotic developed for treating Clostridium difficile infection. We aimed to investigate the safety and efficacy of cadazolid compared with vancomycin in patients with C difficile infection. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afd598dee328c530b621f67ed413d277
https://doi.org/10.1016/s1473-3099(18)30614-5

Role of cephalosporins in the era of Clostridium difficile infection

Autor: Jane Freeman, Emilio Bouza, James D. Chalmers, Mark H. Wilcox, Carl Erik Nord

Publikováno v: Journal of Antimicrobial Chemotherapy
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

The incidence of Clostridium difficile infection (CDI) in Europe has increased markedly since 2000. Previous meta-analyses have suggested a strong association between cephalosporin use and CDI, and many national programmes on CDI control have focused

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5113e21e1112b96cd8eb4ba61cd912ba
http://europepmc.org/articles/PMC5161048

Clostridium difficile recurrences in Stockholm

Autor: Carl Erik Nord, Kristina Ellström, Staffan Sandell, Mamun-Ur Rashid, Andrej Weintraub, Christina Jorup-Rönström

Publikováno v: Anaerobe. 38:97-102

Sixty-eight hospital-admitted patients with a first episode of Clostridium difficile infection (CDI) were included and followed up during 1 year. Faeces samples were collected at 1, 2, 6 and 12 months after inclusion and analyzed for the presence of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8076de3bda011bddb58374bbec1a1fa
https://doi.org/10.1016/j.anaerobe.2016.01.005